[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
[2] Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32.
[3] Yi Z, Vaupel JW, Xiao Z, Zhang C, Liu Y. The Healthy Longevity Survey and the Active Life Expectancy of the Oldest Old in China. Popul Engl Selection. 2001;13(1):95-116.
[4] Laurie J, G Moertel C, R Fleming T, S Wieand H, E Leigh J, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 11/01;7:1447-56.
[5] Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. The New England journal of medicine. 1990 Feb 8;322(6):352-8.
[6] Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England journal of medicine. 2004 Jun 3;350(23):2343-51.
[7] Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15;22(10):1797-806.
[8] Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (London, England). 2007 Dec 15;370(9604):2020-9.
[9] Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. Journal of general internal medicine. 2011 Jul;26(7):783-90.
[10] Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol. 2009 Sep;71(3):249-57.
[11] Droz JP, Aapro M, Balducci L. Overcoming challenges associated with chemotherapy treatment in the senior adult population. Critical Reviews in Oncology/hematology. 2008;68(1):S1-S8.
[12] Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg. 2009;208(2):202-9.
[13] McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013 Jul 10;31(20):2600-6.
[14] Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. 2014. 2014 2014-09-02;59(5):38.
[15] Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma: Importance of lactic dehydrogenase level, performance status, and white blood cell count. The American Journal of Medicine. 1983 1983/05/01/;74(5):786-94.
[16] Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002 Oct;236(4):416-21; discussion 21.
[17] Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol. 2013 Dec 14;19(46):8515-26.
[18] Crosara Teixeira M, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clinical colorectal cancer. 2015 Mar;14(1):52-7.
[19] Lavin P, Mittelman A, Douglass Jr H, Engstrom P, Klaassen D. Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An eastern cooperative oncology group report. Cancer. 1980 1980/10/01;46(7):1536-43.
[20] Luo J, Lin HC, He K, Hendryx M. Diabetes and prognosis in older persons with colorectal cancer. Br J Cancer. 2014;110(7):1847-54.
[21] Huang YC, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol. 2011 Feb;137(2):211-20.
[22] Song E, Chen J, Ou Q, Su F. Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. American journal of surgery. 2001 Jun;181(6):529-33.
[23] Qiu H-B, Zhang L-Y, Zeng Z-L, Wang Z-Q, Luo H-Y, Keshari RP, et al. HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol. 2011;17(6):804-8.
[24] Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006 Aug;10(2):99-111.
[25] Tordjmann T, Soulie A, Guettier C, Schmidt M, Berthou C, Beaugrand M, et al. Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver. 1998 Dec;18(6):391-7.
[26] Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. The New England journal of medicine. 2001 Oct 11;345(15):1091-7.
[27] Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L. Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. Ann Surg Oncol. 2014 Aug;21(8):2636-41.
[28] Lund CM, Nielsen D, Dehlendorff C, Christiansen AB, Ronholt F, Johansen JS, et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1(5):e000087.
[29] Abdel-Rahman O, Ahmed O. Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. Int J Colorectal Dis. 2019 Apr;34(4):675-80.
[30] Bouvier AM, Launoy G, Lepage C, Faivre J. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Alimentary Pharmacology & Therapeutics. 2005;22(3):233.
[31] Ayanian JZ, Zaslavsky AM, Fuchs CS, Edward G, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. Journal of Clinical Oncology. 2003;21(7):1293-300.
[32] Sundararajan V, Grann VR, Jacobson JS, Ahsan H, Neugut AI. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer Journal. 2001;7(3):213